Article -> Article Details

The Legal Basis for the QPPV Role

The QPPV requirement is defined by EU pharmaceutical legislation, specifically Directive 2001/83/EC and Regulation (EC) No 726/2004. The Good Pharmacovigilance Practices (GVP) provide detailed guidelines, particularly in Module I regarding pharmacovigilance systems and Module II related to the Pharmacovigilance System Master File (PSMF), as per Commission Implementing Regulation (EU) No 520/2012. Each MAH must have a qualified person for pharmacovigilance, designated in both the marketing authorization application and the PSMF.

1. Residence and Place of Operation

The QPPV must be located within the European Union or European Economic Area, which poses challenges for non-EU companies. This requirement affects the PSMF’s location and the supervisory authority responsible for the PV system inspection.

2. Qualifications and Experience

The QPPV requires documented experience in pharmacovigilance, including expertise in medical evaluation, epidemiology, and risk management. If lacking specific expertise, the MAH must provide appropriate documented support. A CV, training summary, and job description must be maintained and available for inspection.

3. Permanent and Continuous Availability

The QPPV must be fully available at all times, including outside regular hours, to address safety concerns and regulatory requests. Proper back-up arrangements and a qualified deputy are essential for covering absences, and these arrangements must be documented in the PSMF.

4. Overview and Authority

The QPPV must possess adequate authority to impact the quality system and PV activities within the company. This includes access to safety data, participation in reviewing risk management plans and periodic safety update reports, oversight of signal management, and the ability to raise concerns to senior management. Inspectors routinely verify that this authority is genuinely exercised, not merely theoretical.

Responsibility for the PV System

The QPPV is tasked with establishing and maintaining the MAH’s pharmacovigilance system, overseeing the safety profile and emerging concerns of authorized products. Responsibilities include managing the PSMF, understanding risk minimization measures and post-authorization safety study commitments, and acting as a contact point for competent authorities, especially during inspections.

Individual Member States may necessitate a PV contact person, who operates under the QPPV’s supervision to facilitate local communication with the national authority. As requirements differ by country, MAHs must understand local expectations when operating across multiple Member States.

Common Challenges Companies Face

Across inspections and regulatory interactions, several issues arise repeatedly:

•  Appointing a QPPV who is not based in the EU/EEA or has limited involvement in pharmacovigilance oversight can pose compliance risks.
• Inadequate backup and deputy arrangements leave critical gaps during absences.
• Outdated or inconsistent QPPV information may be present in the Pharmacovigilance System Master File (PSMF), EudraVigilance registration, and authorization dossiers.
• Oversight of PV activities is inadequately defined when delegated to vendors and licensing partners. Additionally, documentation regarding the QPPV oversight—such as meeting minutes, review records, and escalation trails—is poorly maintained.

As companies grow or change their product acquisition and pharmacovigilance outsourcing models, structural issues often emerge, highlighting the need to reassess QPPV resourcing and support.

Outsourcing the QPPV Role:

Many MAHs, especially small to mid-sized companies and those without an EU presence, opt to hire external providers for QPPV services. While this is allowed, the MAH remains legally responsible for its pharmacovigilance system. Essential elements for a successful outsourcing arrangement include a clear contract outlining the QPPV’s duties, established communication and escalation pathways, documented MAH oversight of the QPPV, confirmation of deputy and backup cover, and alignment with the PSMF and quality system documentation.

Zenovel’s EU QPPV Services

As we follow local QPPV services, Zenovel aids pharmaceutical companies in developing and reinforcing our EU QPPV arrangements by integrating regulatory expertise, ensuring the safety of the pharmaceutical goods in European nations.